ClinicalTrials.gg
RecruitingNCT07943065Crypto PulseONUpdated Nov 17, 2026

A Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke Patients

An observational study in Cryptogenic Stroke and Atrial Fibrillation (Prevention of Stroke), sponsored by University Hospitals Coventry and Warwickshire NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospitals Coventry and Warwickshire NHS Trust · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Ischemic Stroke with a site in United Kingdom — 14 open to participants now, 20 under way, 5 of them phase 3. Ischemic Stroke · United Kingdom.

Planned enrollment
33rd of 34
12 · median 430
Started
2026
with 1 other
Observational
34 of 89
7 open now
Primary completion
2027-01
later than 9 of 19 live
Registered
89th of 89
by date

Among the 89 studies in Ischemic Stroke with a site in United Kingdom, this one is the 33rd largest by planned enrollment of the 34 observational ones that give a count, is one of 2 that started in 2026, is one of 34 observational ones, reaches primary completion later than 9 of the 19 other live ones, and was the 89th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

14 of the 89 studies in Ischemic Stroke with a site in United Kingdom are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Ischemic Stroke with a site in United Kingdom, or all of them as a file.
02

Study summary

To evaluate the usability of the Pulse ON wearable device in patients with cryptogenic stroke/TIA

Read the detailed description

The research project aims to evaluate the usability of a new device for detecting heart rhythm disturbances, especially atrial fibrillation (AF) in people who have had a stroke or mini-stroke (transient ischaemic attack [TIA]) of unknown cause (cryptogenic stroke). AF can be a major cause of disabling strokes and AF-related stroke risk is significantly reduced by starting specific blood thinners called anticoagulants.

Stroke is a major public health concern worldwide, with approximately 100,000 cases annually in the UK alone, making it a leading cause of death and disability. Around 38,000 stroke-related deaths occur each year, and many survivors experience significant long-term impairment. The vast majority (\~90%) are ischaemic strokes, yet in 20-40% of cases, no definitive underlying cause is identified, despite extensive evaluation. These cryptogenic stroke cases remain a diagnostic challenge. Cryptogenic strokes are more common in younger stroke patients (\<60 years) but can affect all age groups.

AF is the most common arrhythmia and a well-established cause of ischaemic stroke, responsible for 15-30% of cases. However, in cryptogenic stroke, AF often goes undiagnosed because it can come and go (i.e. is paroxysmal) and can be asymptomatic in nature, with episodes that can last for short periods of time but carry high risk of stroke. Early and accurate diagnosis of AF is crucial, as clinical trials have demonstrated the efficacy of oral anticoagulation in significantly reducing stroke risk. Thus, identifying AF in cryptogenic stroke patients can directly impact management by shifting treatment towards anticoagulation.

Background. Detecting AF in cryptogenic stroke is a major challenge and many methods fail to capture episodes of AF that come and go (paroxysmal). Conventional AF detection methods, such as in-hospital cardiac monitoring, serial ECGs, Holter monitors, external event recorders, wearable devices and implantable loop recorders (ILRs), vary in effectiveness. ILRs are small devices (the size of a pen-lid) implanted under the skin of the left chest wall and have a battery life of around three years. They have demonstrated superior diagnostic sensitivity, as highlighted in the CRYSTAL-AF trial, which showed their advantage over standard monitoring in cryptogenic stroke (AF detection rate of 12.4% for ILRs vs 2% for standard monitoring at 12 months). However, ILRs are invasive (which comes with its own procedure-related risks), costly, and may not be suitable for all patients.2 We want to evaluate a different type of AF detection device (the PulseON Arrhythmia Monitor System) that is not currently used in standard care, one that's wrist worn and non-invasive.

Proposed trial We propose a single centre, single arm feasibility pilot study designed to evaluate how practical and user friendly it is for participants to use the PulseON Arrhythmia Monitor System for detecting AF in addition to their normal standard of care. The study will explore whether participants can wear the device as intended, respond to alerts and successfully carry out ECG recordings using the system, whilst capturing their user experience and having their heart tracings closely monitored by health care professionals.

Trial population At UHCW NHS Trust, we manage approximately 1,400 strokes annually (with 350 classified as cryptogenic), many of whom will need to be monitored for AF. While most patients undergo Holter monitoring for AF, a smaller subset receive ILRs but their use is limited due their cost and invasive nature. The introduction of this PulseON device could significantly enhance AF detection, improving patient outcomes, be more cost-effective and optimise resource utilisation within our hospital and the broader NHS. We plan to evaluate whether cardiac monitoring with the PulseON system is feasible in patients with cryptogenic stroke/TIA. This evaluation project may inform wider research into this device and potential NHS implementation.

Treatment / Intervention We aim to recruit twelve patients who have experienced a cryptogenic ischaemic stroke or TIA within the past six months for this project. All patients who participate in the project will receive conventional standard of care investigations (Holter monitoring or ILR) in addition to the PulseON Arrhythmia monitoring system. The data collected will include experience of device usability via an MS forms questionnaire and a follow-up patient interview, baseline demographics, usability data and any newly detected arrhythmia observed from the heart tracing data, in particular AF (defined as an episode of AF lasting >30seconds). Any arrhythmia documented from the PulseON device will be uploaded and stored in an encrypted and secure cloud-based server.

Participants heart tracing data will be collected and reviewed by a suitably qualified healthcare professional within the study team (primarily the Principal Investigator).The reviewer will assess any detected cardiac events to determine their clinical significance and, when appropriate, will escalate relevant findings to the participant's clinical care team. This process ensures that any new or emerging information arising from the study is used to support and inform the provision of standard clinical care for participants.

03

Conditions studied

  • Cryptogenic Stroke
  • Atrial Fibrillation (Prevention of Stroke)

Keywords

  • AF detection
  • Stroke prevention
  • Rhythm monitoring
  • Wearable ECG monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with cryptogenic stroke/TIA

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (>18yrs old) diagnosed with cryptogenic stroke /
  • Baseline (ECG), Holter monitor and echocardiogram as part of the standard of care cardiac work-up in the diagnosis of cryptogenic stroke

Exclusion criteria

Exclusion Criteria:

  • Patients unwilling or unable to wear the PulseON arrhythmia detection device.
  • Known pre-existing AF or atrial arrhythmia diagnosis.
  • Participants without capacity will be excluded from this study.
  • Participants who are pregnant will be excluded from this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12 participants (estimated)
Patient registry
No

Interventions

  • DeviceWearable Heart rhythm monitoring device (PulseON)

    Wearable heart rhythm monitoring device to detect AF

06

What researchers measure

Primary outcomes

  1. Usability & Feasibility of PulseON wearable device

    We will collect patient questionnaires and perform patient interviews to gather data on the PulseON device for usability and feasibility data. Formal feedback from health professionals who follow up the trial participants via the PulseON arrhythmia monitoring system online will be obtained.

    Time frame: 1 month minimum

Secondary outcomes

  1. The prevalence of AF in people who have had cryptogenic ischaemic stroke or TIA.

    The ability of Pulse ON in detecting AF on ECG and how it differs from the standard of care (ECG, Holter monitoring or ILR)

    Time frame: 1 month

  2. Baseline characteristics of cohort

    Baseline demographic and clinical characteristics

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2027, 4 months after the start.

Of 397 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 4 months is below that.

Counting every sponsor, half of 439 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartActual
Sep 16, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943065
Lead sponsor
University Hospitals Coventry and Warwickshire NHS Trust
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Sep 16, 2026
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Andrew White
Contact
andrew.white@uhcw.nhs.uk
02476968582
Faizel Osman
study director · University Hospital Coventry & Warwickshire
Ven G Lim
principal investigator · University Hospital Coventry & Warwickshire

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion